Tango Therapeutics, Inc.
NASDAQ:TNGX
Overview | Financials
Company Name | Tango Therapeutics, Inc. |
Symbol | TNGX |
Currency | USD |
Price | 3.1 |
Market Cap | 332,995,800 |
Dividend Yield | 0% |
52-week-range | 2.7 - 13.005 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Barbara L. Weber M.D. |
Website | https://www.tangotx.com |
An error occurred while fetching data.
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD